{"transactions":[{"id":940971,"issuer":{"id":7830,"kind":"organization","name":"HeartSciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-13T01:03:32.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents Restricted Stock Units (the \"RSUs\") granted to the Reporting Person under the Issuer's 2023 Equity Incentive Plan (as amended, the \"Plan\") pursuant to the approval of the Issuer's board of directors. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock, $0.001 par value per share, upon satisfaction of the Conditions (as defined below)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs shall vest subject to the satisfaction of all of the following conditions (the \"Conditions\"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the \"Initial Vesting Date\") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an \"Additional Initial Vesting Date\" and together with the Initial Vesting Date, the \"Vesting Dates\"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs shall vest subject to the satisfaction of all of the following conditions (the \"Conditions\"): (i) approval by the Issuer's shareholders of any amendment or modification to or restatement of the Plan, which, among other things, contemplates the award of the RSUs; and (ii) (x) 1/2 of the RSUs shall vest on the one-year anniversary of the grant date (the \"Initial Vesting Date\") and (y) thereafter, 1/8th of the RSUs shall vest on each subsequent quarterly anniversary of the Initial Vesting Date (each an \"Additional Initial Vesting Date\" and together with the Initial Vesting Date, the \"Vesting Dates\"), such that all of the RSUs shall fully vest on the two-year anniversary of the grant date in each case provided that the Reporting Person is continuously serving on the Board through each applicable Vesting Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"100% of the RSUs shall vest (i) in the event of a Change of Control (as defined in the Plan) or (ii) if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the date hereof."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-26-003616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000121390026003616/ownership.xml","form_type":"4"}},{"id":1088545,"issuer":{"id":7830,"kind":"organization","name":"HeartSciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-12T01:00:04.000Z","date":"2025-07-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These options were granted to the Reporting Person effective as of July 9, 2025 (the \"Effective Date\"), pursuant to the approval of the compensation committee of the Issuer's board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These options were granted to the Reporting Person effective as of July 9, 2025 (the \"Effective Date\"), pursuant to the approval of the compensation committee of the Issuer's board of directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan, as amended (the \"2023 Plan\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement."}],"balance_after":25000,"derivative":{"exercise_price":4.37,"expiration_date":"2035-07-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-25-063411","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000121390025063411/ownership.xml","form_type":"4"}},{"id":1298734,"issuer":{"id":7830,"kind":"organization","name":"HeartSciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-21T22:17:26.000Z","date":"2025-01-16","kind":"grant","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These options were granted to the Reporting Person effective as of January 16, 2025 (the \"Effective Date\"), pursuant to the approval of the compensation committee of the Issuer's board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These options were granted to the Reporting Person effective as of January 16, 2025 (the \"Effective Date\"), pursuant to the approval of the compensation committee of the Issuer's board of directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement."}],"balance_after":6000,"derivative":{"exercise_price":3.33,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001213900-25-005092","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000121390025005092/ownership.xml","form_type":"4"}},{"id":1758970,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-17T20:09:42.000Z","date":"2023-10-15","kind":"grant","planned":false,"acquired":true,"shares":293250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase 73,313 shares vest on 10/15/2024, and the remaining 219,937 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months."}],"balance_after":293250,"derivative":{"exercise_price":2.4,"expiration_date":"2033-10-15","underlying":"Class A Common Stock","underlying_shares":293250},"source":{"system":"sec-edgar","filing":"0001062993-23-019440","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000106299323019440/form4.xml","form_type":"4"}},{"id":1941617,"issuer":{"id":7830,"kind":"organization","name":"HeartSciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-03-22T23:56:39.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These options were granted to the Reporting Person effective as of March 20, 2023 (the \"Effective Date\"), pursuant to the approval of the Issuer's board of directors (the \"Board\") on March 20, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These options were granted to the Reporting Person effective as of March 20, 2023 (the \"Effective Date\"), pursuant to the approval of the Issuer's board of directors (the \"Board\") on March 20, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options shall vest in four equal increments, with the first tranche of the options vesting on June 20, 2023 (the \"Initial Vesting Date\"), with an additional one-fourth of the options vesting on each successive three-month anniversary of the Initial Vesting Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the \"2023 Plan\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options expire ten years from the Effective Date, unless terminated sooner in accordance with the 2023 Plan or the underlying options grant agreement."}],"balance_after":50000,"derivative":{"exercise_price":0.97,"expiration_date":"2033-03-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-009454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000089924323009454/doc4.xml","form_type":"4"}},{"id":2754231,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2021-04-07T20:10:35.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025849","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919121025849/doc4.xml","form_type":"4"}},{"id":2915472,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T00:15:07.000Z","date":"2021-01-06","kind":"sale","acquired":false,"shares":34900,"price":0.9,"value":31410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020."}],"balance_after":80003,"source":{"system":"sec-edgar","filing":"0001209191-21-002370","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919121002370/doc4.xml","form_type":"4"}},{"id":2915471,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T00:15:07.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":100,"price":0.9,"value":90.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020."}],"balance_after":114903,"source":{"system":"sec-edgar","filing":"0001209191-21-002370","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919121002370/doc4.xml","form_type":"4"}},{"id":3100851,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants","published_at":"2020-06-24T12:22:41.000Z","date":"2020-06-23","kind":"other","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5051,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-038681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120038681/doc4.xml","form_type":"4"}},{"id":3100850,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-24T12:22:41.000Z","date":"2020-06-23","kind":"other","acquired":true,"shares":5000,"price":0.87,"value":4350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":115003,"source":{"system":"sec-edgar","filing":"0001209191-20-038681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120038681/doc4.xml","form_type":"4"}},{"id":3114746,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T11:38:00.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":8.744,"price":1143.68,"value":10000.33792,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001209191-20-035438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120035438/doc4.xml","form_type":"4"}},{"id":3114745,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-10T11:38:00.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":10350,"price":0.87,"value":9004.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":110003,"source":{"system":"sec-edgar","filing":"0001209191-20-035438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120035438/doc4.xml","form_type":"4"}},{"id":3177923,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-04-13T20:39:31.000Z","date":"2020-04-09","kind":"grant","acquired":true,"shares":79653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted in lieu of a portion of the Reporting Person's cash salary. Subject to continued employment, the restricted stock units vest each day, pro rata based on the number of days between the grant date and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of\nthe Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested restricted stock units."}],"balance_after":99653,"source":{"system":"sec-edgar","filing":"0001209191-20-024213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120024213/doc4.xml","form_type":"4"}},{"id":3300104,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2020-01-28T22:02:25.000Z","date":"2020-01-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 25, 2021."}],"balance_after":20000,"derivative":{"exercise_price":1.71,"expiration_date":"2030-01-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-005185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120005185/doc4.xml","form_type":"4"}},{"id":3345250,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants","published_at":"2019-12-11T22:54:06.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":10051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock."}],"balance_after":10051,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":10051},"source":{"system":"sec-edgar","filing":"0001209191-19-060093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119060093/doc4.xml","form_type":"4"}},{"id":3345249,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-12-11T22:54:06.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":8.744,"price":1143.68,"value":10000.33792,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%.  The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A preferred stock has no expiration date."}],"balance_after":8.744,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":10051},"source":{"system":"sec-edgar","filing":"0001209191-19-060093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119060093/doc4.xml","form_type":"4"}},{"id":3345248,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-12-11T22:54:06.000Z","date":"2019-12-11","kind":"grant","acquired":true,"shares":138375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date."}],"balance_after":138375,"derivative":{"exercise_price":0.9,"expiration_date":"2029-12-11","underlying":"Common Stock","underlying_shares":138375},"source":{"system":"sec-edgar","filing":"0001209191-19-060093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119060093/doc4.xml","form_type":"4"}},{"id":3404459,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-09-30T20:16:22.000Z","date":"2019-09-27","kind":"purchase","acquired":true,"shares":10000,"price":1.18,"value":11800.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-19-051091","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119051091/doc4.xml","form_type":"4"}},{"id":3429226,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-08-26T20:18:56.000Z","date":"2019-08-23","kind":"purchase","acquired":true,"shares":5000,"price":1.55,"value":7750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.59, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-19-047405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119047405/doc4.xml","form_type":"4"}},{"id":3429225,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-08-26T20:18:56.000Z","date":"2019-08-22","kind":"purchase","acquired":true,"shares":5000,"price":1.56,"value":7800.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-047405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119047405/doc4.xml","form_type":"4"}},{"id":3525988,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2019-05-15T21:00:19.000Z","date":"2019-05-13","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in three equal annual installments beginning on May 13, 2020."}],"balance_after":56000,"derivative":{"exercise_price":1.38,"expiration_date":"2029-05-13","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001209191-19-030069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919119030069/doc4.xml","form_type":"4"}},{"id":3729067,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2018-12-17T21:40:18.000Z","date":"2018-12-13","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in twelve equal quarterly installments beginning on March 13, 2019."}],"balance_after":35000,"derivative":{"exercise_price":2.25,"expiration_date":"2022-12-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-18-062953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919118062953/doc4.xml","form_type":"4"}},{"id":3763171,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Convertible Promissory Note","published_at":"2018-11-15T21:18:39.000Z","date":"2018-11-13","kind":"exercise","acquired":false,"price":10000,"reported_value":10000,"ownership":{"direct":false,"nature":"By StoryCorp Consulting"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Convertible Promissory Note (the \"Note\"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%."}],"derivative":{"exercise_price":1.68,"expiration_date":"2018-12-31","underlying":"Common Stock","underlying_shares":5953},"source":{"system":"sec-edgar","filing":"0001209191-18-058723","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919118058723/doc4.xml","form_type":"4"}},{"id":3763170,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-15T21:18:39.000Z","date":"2018-11-13","kind":"exercise","acquired":true,"shares":5953,"price":1.68,"value":10001.04,"ownership":{"direct":false,"nature":"By StoryCorp Consulting"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2)."}],"balance_after":24786,"source":{"system":"sec-edgar","filing":"0001209191-18-058723","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919118058723/doc4.xml","form_type":"4"}},{"id":3878734,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants","published_at":"2018-07-02T23:37:12.000Z","date":"2018-06-28","kind":"grant","acquired":true,"shares":2480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By StoryCorp Consulting"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Warrants were issued for no additional consideration in connection with the offer and sale of the Note."}],"balance_after":2480,"derivative":{"exercise_price":2.52,"exercise_date":"2018-12-28","expiration_date":"2021-06-28","underlying":"Common Stock","underlying_shares":2480},"source":{"system":"sec-edgar","filing":"0001209191-18-040509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919118040509/doc4.xml","form_type":"4"}},{"id":3878733,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Convertible Promissory Note","published_at":"2018-07-02T23:37:12.000Z","date":"2018-06-28","kind":"grant","acquired":true,"price":10000,"reported_value":10000,"ownership":{"direct":false,"nature":"By StoryCorp Consulting"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Convertible Promissory Note (the \"Note\") is convertible into the Issuer's common stock at a conversion price equal to the lesser of (a) the lowest per share price at which common stock is sold by the Issuer in a sale resulting in aggregate gross cash proceeds of at least $7.0 million (a \"Qualified Financing\"), less a discount of 20%, or (b) $2.016, but in any event no less than a conversion price floor of $1.40, which conversion price is subject to adjustment in certain circumstances in accordance with the terms of the Note."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The principal amount of the Note will automatically convert into shares of the Issuer's common stock (i) upon the consummation of a Qualified Financing or (ii) if the holders of a majority of the aggregate principal amount of outstanding Convertible Promissory Notes elect to convert such notes at any time until three days prior to a Qualified Financing. Additionally, the reporting person is entitled to convert the principal amount of the Note into common stock (i) at any time until three days prior to the consummation of a Qualified Financing or (ii) if a material Event of Default (as defined in the Note) shall have occurred and be continuing. In each case, conversion is subject to the terms and provisions of the Note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares of common stock shown in Column 7 assumes a conversion price of $2.016, which is subject to adjustment in certain circumstances (see Footnote 1)."}],"derivative":{"expiration_date":"2018-12-31","underlying":"Common Stock","underlying_shares":4961},"source":{"system":"sec-edgar","filing":"0001209191-18-040509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919118040509/doc4.xml","form_type":"4"}},{"id":4318417,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2017-05-17T01:16:14.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7000,"derivative":{"exercise_price":5,"exercise_date":"2017-05-12","expiration_date":"2022-05-12","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-17-032899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919117032899/doc4.xml","form_type":"4"}},{"id":4318416,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2017-05-17T01:16:14.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These Stock Options become exercisable in twelve equal quarterly installments beginning on August 12, 2017."}],"balance_after":15000,"derivative":{"exercise_price":5,"expiration_date":"2021-05-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-032899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919117032899/doc4.xml","form_type":"4"}},{"id":4318415,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-05-17T01:16:14.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":18833,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By StoryCorp Consulting"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Award of restricted stock granted pursuant to the Issuer's 2016 Omnibus Incentive Plan."}],"balance_after":18833,"source":{"system":"sec-edgar","filing":"0001209191-17-032899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919117032899/doc4.xml","form_type":"4"}}]}